The Traderszone Network

2 June, 2015 by The TZ Newswire Staff Comments Off on More Market Nothingness and Biotech Has Me Cautious

More Market Nothingness and Biotech Has Me Cautious

This maddening sideways chop continues and the best “risk on” sector, biotech, looks heavy and tired.  The leaders in this space are heavy, AMGN has a bearish head and shoulder pattern going on and CELG and BIIB just cant stop stepping on their feet. GILD acts the best of the big four biotechs.  The other biggie, REGN, continues to hang on so far.

read more

2 June, 2015 by The TZ Newswire Staff Comments Off on Why Windstream Holdings, Inc. Fell 26% in May

Why Windstream Holdings, Inc. Fell 26% in May

Is it meaningful, or just another random walk down Wall Street?

2 June, 2015 by The TZ Newswire Staff Comments Off on TIAA-CREF: What This $8.6 Billion Trust Has Been Selling

TIAA-CREF: What This $8.6 Billion Trust Has Been Selling

It can pay off to keep an eye on TIAA-CREF and other big investors to see what they’re doing.

2 June, 2015 by The TZ Newswire Staff Comments Off on "If It Looks Like A Duck" – The Man In The Moon: Part 2

"If It Looks Like A Duck" – The Man In The Moon: Part 2

Submitted by Paul Brodsky of Macro Allocation, Inc.

In part 2 of the “Man in the Moon” series we look at Paul Volcker’s roundtrip – monetary policies and their impacts from 1971 through the Great Leveraging to today. Part 1 can be found here.

If it Looks Like a Duck…

read more

2 June, 2015 by The TZ Newswire Staff Comments Off on DoNT WaiT UNTiL IT’S Too LaTe…

DoNT WaiT UNTiL IT’S Too LaTe…

read more

2 June, 2015 by The TZ Newswire Staff Comments Off on Dollar mauled as euro leads vicious short squeeze

Dollar mauled as euro leads vicious short squeeze

The dollar was lower as hopes for Greece talks progress and a spike in European yields combined to give the euro its biggest gain in three months.

2 June, 2015 by The TZ Newswire Staff Comments Off on Cramer: Buy on the dip of high fliers?

Cramer: Buy on the dip of high fliers?

Jim Cramer goes off the charts to find out if it’s time for investors to buy on the weakness of three popular stocks.